CN114214353A - Method for producing human recombinant arginase I by fermentation - Google Patents

Abstract

The invention discloses a method for producing human recombinant arginase I by fermentation, which comprises the following steps: (1) inoculating the seed liquid of the human recombinant arginase I producing strain into a fermentation culture medium for fermentation culture, and performing fermentation culture until the OD of the fermentation liquid diluted by 100 times is obtained₆₀₀When the value is 0.50-0.60, cooling to 22 ℃, adding IPTG into the system, and carrying out induction culture for 20-28 h; (2) adjusting the pH value of the culture solution after induction culture to 7.1-7.3, crushing, filtering by a ceramic membrane, and collecting filtrate; subjecting the filtrate to affinity chromatography with nickel column, adding bovine thrombin solution, cutting, eluting with normal saline, and collectingEluting the solution; and sequentially passing the eluent through benzamidine-sepharose resin and Sephadex G-150 Sephadex, desalting, concentrating and drying to obtain the human recombinant arginase I. According to the invention, the yield and the enzyme activity of the human recombinant arginase I produced by fermentation are obviously improved by modifying the human recombinant arginase I producing strain and optimizing the fermentation production process.

Description

Method for producing human recombinant arginase I by fermentation

Technical Field

The invention relates to the technical field of genetic engineering, in particular to a method for producing human recombinant arginase I by fermentation.

Background

Arginase I (Arginase I) is mainly located in cytoplasm of liver organs of mammals, is an enzyme in urea circulation, can catalyze arginine hydrolysis to produce ornithine and urea, and plays an important role in nitrogen metabolism of organisms. Arginine, a semi-essential amino acid, is only required for rapidly growing tissues, especially tumor tissues. Arginase I carries out nutrition deprivation on tumor cells by decomposing arginine, and has small influence on normal tissues; numerous in vivo and in vitro experiments prove that arginase I has a remarkable effect of inhibiting tumor cell division, so that arginase I is a good anti-tumor medicament and has a wide market application prospect.

The humanized enzyme is the first choice for medicinal enzyme because of its low antigenicity. Human arginase I achieved prokaryotic expression in 1990, but limited by the development of the expression system at that time, the ability of the promoters employed by researchers to control transcription, both at the expression level and under non-inducible conditions, was to be improved. The Nanjing university of science and engineering in 2006 tries to express human arginase I in Pichia engineering bacteria, but the expressed protein is not secreted outside yeast cells, and the expression level is low. The obtained full-length cDNA of the human arginase I is cloned to a prokaryotic high-expression vector in 2015 by Rieger university Leyipeng, and the expression of the human liver arginase I is carried out by an automatic induction system, wherein the yield of the recombinant human arginase I is 48.5mg per liter of bacterial liquid, and the purity of the recombinant human arginase I is over 95 percent.

However, most of the above studies have been still in the laboratory level, and the yield of recombinant human arginase I is low, and if it is applied to industrial production, it is difficult to achieve satisfactory effect of producing recombinant human arginase I by fermentation due to the effect of scale-up effect.

Disclosure of Invention

In view of the above prior art, the present invention aims to provide a method for producing human recombinant arginase I by fermentation. According to the invention, the yield and the enzyme activity of the human recombinant arginase I produced by fermentation are obviously improved by modifying the human recombinant arginase I producing strain and optimizing the fermentation production process.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect of the present invention, there is provided a method for the fermentative production of human recombinant arginase I, comprising the steps of:

(1) inoculating the seed liquid of the human recombinant arginase I producing strain into a fermentation culture medium for fermentation culture, wherein the temperature of the fermentation culture is 32-34 ℃, the pH value is 6.8-7.2, the Dissolved Oxygen (DO) is 20-40%, and the stirring speed is 180-220 rpm; performing fermentation culture until the OD of the fermentation liquid after being diluted by 100 times₆₀₀When the value is 0.50-0.60, cooling to 22 ℃, adding IPTG into the system to ensure that the final concentration of the IPTG in the system is 0.2mmol/L, and carrying out induced culture for 20-28 h;

monitoring the glycerol content of the system in the culture process, starting to add supplementary materials when the glycerol content of the system is less than or equal to 1.0g/L, and keeping the glycerol content of the system at 0.5-1g/L by feeding supplementary materials;

(2) adjusting the pH value of the culture solution after induction culture in the step (1) to 7.1-7.3, and crushing the culture solution by a homogenizer; passing the crushed mixed homogenate of the cells through a ceramic membrane, and collecting filtrate; diluting the filtrate until the concentration of human recombinant arginase I in the filtrate is 8-12g/L, carrying out affinity chromatography by adopting a nickel column, carrying out column hanging on the diluted filtrate, then adding a bovine thrombin solution for cutting, eluting by using normal saline, and collecting eluent; passing the eluate through benzamidine-sepharose resin to remove bovine thrombin; passing the eluent which passes through the benzamidine-sepharose resin through Sephadex G-150 Sephadex, and collecting liquid flowing out for 3-8 h; desalting the collected liquid by electrodialysis, collecting fresh water, concentrating and drying to obtain the human recombinant arginase I.

Preferably, in step (1), the human recombinant arginase I-producing strain is constructed by the following method:

carrying out double digestion treatment on the pHT304 plasmid by Nde I and HincII, and integrating a Pg3 promoter sequence shown in SEQ ID NO.1 onto the pHT304 plasmid after double digestion treatment to obtain a plasmid pHT304-Pg3, wherein the nucleotide sequence of the plasmid pHT304-Pg3 is shown in SEQ ID NO. 2; carrying out double enzyme digestion treatment on the plasmid pHT304-Pg3 by using Sph I and Sac I, integrating the arg1 gene into the plasmid pHT304-Pg3 after double enzyme digestion treatment to obtain a recombinant expression vector (pHT304-Pg3-arg1), wherein the nucleotide sequence of the recombinant expression vector is shown as SEQ ID NO. 8;

and introducing the obtained recombinant expression vector into bacillus subtilis to construct and obtain the human recombinant arginase I producing strain.

More preferably, the arg1 gene is optimized and modified, aspartic acid at position 158 of the human recombinant arginase I is mutated into glutamic acid, a coding nucleotide sequence is obtained again based on the amino acid sequence of the mutated human recombinant arginase I, and codon optimization is carried out; then, a signal peptide sequence is added in the optimized nucleotide sequence, and a thrombin cutting site and 10His tails are inserted. The nucleotide sequence of the arg1 gene after the final optimization and modification treatment is shown as SEQ ID NO. 7.

Preferably, in step (1), the fermentation medium has the following composition: peptone 12g/L, glycerin 10g/L, yeast extract 8g/L, sodium chloride 3g/L, ammonium sulfate 2.5g/L, dipotassium hydrogen phosphate trihydrate 4g/L, ferric ammonium citrate 0.3g/L, citric acid 2.1g/L, magnesium sulfate heptahydrate 0.5g/L, and ampicillin 100 ppm.

Preferably, in the step (1), the feed comprises 400g/L of glycerol, 30g/L of peptone and 100g/L of yeast extract.

Preferably, in the step (2), the specific conditions for adding the bovine thrombin solution for cleavage are as follows: the digestion buffer was cut with 150mM NaCl, pH7.0, digestion temperature 30 ℃ for 10 h.

Preferably, in the step (2), the electrodialysis conditions are as follows: controlling the pH value to be 7.25 and the temperature to be below 40 ℃; when the conductance of the dilute chamber is less than or equal to 1000 mus/cm, the electrodialysis is closed, and fresh water is discharged.

Preferably, in the step (2), the drying is freeze-drying under the following conditions:

pre-freezing: the temperature is reduced by 15 ℃ per minute and is reduced to-35 ℃; quick-freezing: refrigerating the plate layer at-40 ℃, putting the plate layer into a product machine for full-speed refrigeration, and starting vacuumizing after waiting for 2 hours; sublimation drying: controlling the vacuum value at 10-30 Pa; and (3) resolving and drying: slowly heating to +40 ℃, wherein the vacuum value is less than 20 Pa; and (5) closing a vacuum valve between the freeze-drying box and the condenser, observing for 60s, and finishing freeze-drying if the pressure rise is less than 0.5 Pa.

In a second aspect of the invention, there is provided human recombinant arginase I produced by the above method, wherein the amino acid sequence thereof is shown in SEQ ID NO. 5.

The invention has the beneficial effects that:

in order to improve the yield and the enzyme activity of the human recombinant arginase I produced by fermentation and realize industrial production, the invention researches three aspects of enzyme site-directed mutagenesis treatment, strain construction and fermentation process optimization. Specifically, the method comprises the following steps:

(1) the invention firstly adopts a molecular dynamics simulation method to carry out structure optimization on the human recombinant arginase I, and mutates aspartic acid at the 158 th site of the human recombinant arginase I into glutamic acid. Compared with wild human recombinant arginase I, the enzyme activity of the mutated human recombinant arginase I is obviously improved.

(2) Aiming at the human recombinant arginase I after mutation treatment, the invention further constructs a corresponding production strain, selects pHT304 plasmid as basic plasmid, and modifies the basic plasmid, integrates Pg3 promoter into pHT304 plasmid, Pg3 promoter begins to express only after IPTG is added, therefore, after the promoter is replaced, the strain grows fast in the early stage, the time required for entering the stable stage is short, and the expression quantity of the human recombinant arginase I is further improved.

(3) The culture medium is required for providing strains to reproduce and synthesize various metabolites, and the composition of the culture medium has a crucial influence on the success or failure of fermentation. The invention optimizes the composition of the fermentation medium for producing the human recombinant arginase I, and takes glycerol as a unique carbon source. The glycerol is a water-soluble substance, has no viscosity, is easy to operate as a supplementary ingredient in high-density fermentation, and the protein distributed in the fermentation liquor containing the glycerol can be purified by a conventional method without influencing the recovery and regeneration of the filler; glycerol has no function of denaturating protein, and arg I expressed by using glycerol as a carbon source still keeps good biological activity, and the fermentation effect of the arg I is better than that of glucose.

In conclusion, the invention realizes the industrial production of the human recombinant arginase I and obviously improves the yield and the enzyme activity of the human recombinant arginase I by the mutation transformation of the human recombinant arginase I, the construction of production bacteria and the optimization of fermentation process.

Drawings

FIG. 1: a schematic representation of the structure of plasmid pHT304-Pg 3.

FIG. 2: schematic representation of the three-dimensional structure of human arginase I.

FIG. 3: root Mean Square Deviation (RMSD) curves for the protein backbones of wild-type Arginase I (W-Arginase1) and mutant Arginase I (R-Arginase 1).

FIG. 4: effect of different concentrations of DMSO on the initial rate of arginase I catalyzed reactions before and after mutation.

FIG. 5: the structural schematic diagram of the recombinant expression vector (pHT304-Pg3-arg1) constructed by the invention.

FIG. 6: the electrophoresis verification of the recombinant expression vector (pHT304-Pg3-arg1) constructed by the invention.

FIG. 7: the colony PCR of the human recombinant arginase I producing strain constructed by the invention is verified.

FIG. 8: the western blot verification of the constructed human recombinant arginase I production strain; in the figure, the right lane is Marker.

Detailed Description

It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.

In order to make the technical solutions of the present application more clearly understood by those skilled in the art, the technical solutions of the present application will be described in detail below with reference to specific embodiments.

The test materials used in the examples and comparative examples of the present invention are conventional in the art and are commercially available. Wherein:

the Bacillus subtilis used in the present examples and comparative examples was BS168 Bacillus subtilis, which was purchased from North Noro Biotech, Inc., Shanghai.

The methods for constructing recombinant arginase I-producing bacteria of the present invention are all methods that are available in the art of genetic engineering and can be repeatedly performed by those skilled in the art, and therefore, biological preservation thereof is not necessary.

Example 1: construction of human recombinant arginase I producing strain

1. Plasmid transformation:

plasmid pHT304 (purchased from Youbao) was digested simultaneously with Nde I and HincII, and then the promoter Pg3 (SEQ ID NO: 1) was incorporated into the digested plasmid pHT304 to construct plasmid pHT304-Pg3 (FIG. 1).

The plasmid pHT304-Pg3 obtained by construction is single ampicillin resistant, has a lactose operon, and has a nucleotide sequence shown in SEQ ID NO. 2.

The pHT304 plasmid was engineered for the purposes of: firstly, the length of the vector is reduced, and the expression stability of the vector in bacillus subtilis is improved; secondly, the Pg3 promoter is integrated into the pHT304 plasmid, and the Pg3 promoter begins to express only after IPTG is added, so that after the Pg3 promoter is integrated, the strain grows fast in the early stage, the time required for entering a stabilization phase is short, the expression time of the human recombinant arginase I is shortened, and the expression quantity of the human recombinant arginase I is improved; and thirdly, the influence on the growth of the bacillus subtilis after induction expression is reduced.

2. Optimization and modification of arg1 gene:

the amino acid sequence of the human arginase I obtained from the existing database is shown as SEQ ID NO. 3; the nucleotide sequence of the coding gene arg1 is shown in SEQ ID NO. 4.

In order to improve the activity of the human recombinant arginase I, the human recombinant arginase I is structurally optimized by adopting a molecular dynamics simulation method, the aspartic acid at the 158 th site of the human recombinant arginase I is mutated into glutamic acid, and the amino acid sequence of the mutated human recombinant arginase I is shown as SEQ ID NO. 5.

As shown in FIG. 2, aspartic acid (D) at position 158 is protruded outward, and after mutation to glutamic acid (E), it is not protruded outward, and the angle between P and V is also reduced, so the whole structure is more compact.

The Root Mean Square Deviation (RMSD) curves of the protein backbones of wild-type Arginase I (W-Arginase1) and mutant Arginase I (R-Arginase1) are shown in FIG. 3, following a molecular dynamics simulation of 50 ns. The results show that the two are close to the equilibrium state after 15ns, the two are basically in equilibrium after 25ns, and the RMSD value is between 0.13 and 0.15, which indicates that the point mutation has little influence on the whole structure of arginase I.

The results of measuring the effect of different concentrations of DMSO on the initial rates of arginase I catalytic reactions before and after mutation are shown in FIG. 4, and when the DMSO concentration is 30%, the activity of the mutant arginase I is increased by 10.2 times, and the activity of the wild-type arginase I is increased by 4.7 times.

The above results show that: the 158 th aspartic acid of the human recombinant arginase I is mutated into glutamic acid, so that the catalytic activity of the arginase I can be obviously improved.

In order to make the arg1 gene more suitable for a bacillus subtilis expression system, the nucleotide sequence of the arg1 gene for coding the mutated human recombinant arginase I is further subjected to codon optimization; in order to improve the secretory expression of the human recombinant arginase I in the bacillus subtilis, a section of signal peptide is added on the basis of the nucleotide sequence of the arg1 gene after codon optimization, and the specific steps are as follows:

ATGAAAAGATTTTTGTCCACTTTGTTGATTGGAATGATGCTGGTTACATGTGCCTCGCCGGCATTTGCC。(SEQ ID NO.6)

in order to facilitate the separation and purification of the expressed human recombinant arginase I, a thrombin cutting site and a 10His sequence are further added in the nucleotide sequence.

The nucleotide sequence of the arg1 gene after final optimization and modification is shown in SEQ ID NO. 7.

3. Construction of recombinant expression vectors:

the modified plasmid pHT304-Pg3 is subjected to double enzyme digestion treatment by SphI and SacI, and the final optimized and modified arg1 gene (shown in SEQ ID NO. 7) is integrated on the plasmid pHT304-Pg3 subjected to double enzyme digestion treatment to obtain a recombinant expression vector (pHT304-Pg3-arg 1). The schematic structure of the recombinant expression vector is shown in FIG. 5.

The constructed recombinant expression vector was verified by electrophoresis, and the result is shown in FIG. 6. The results show that: the arg1 gene (shown in SEQ ID NO. 7) has been successfully integrated into plasmid pHT304-Pg 3. The nucleotide sequence of the constructed recombinant expression vector (pHT304-Pg3-arg1) is shown in SEQ ID NO.8 through sequencing verification.

4. Construction of human recombinant arginase I producing strain

The constructed recombinant expression vector (pHT304-Pg3-arg1) was introduced into BS168 Bacillus subtilis to obtain a transformant. Transformants were inoculated on AMP plates (LB plates containing 100. mu.g/ml AMP), and single colonies that could grow on the AMP plates were picked up as positive transformants.

And (3) carrying out colony PCR verification and western blot verification on the positive transformants, wherein the colony PCR verification result is shown in figure 7, and the western blot verification result is shown in figure 8. The results show that: the recombinant expression vector constructed in example 3 has been successfully introduced into recipient bacteria.

This proves that: this example successfully constructed a stable human recombinant arginase I producing strain.

Example 2: fermentation production of human recombinant arginase I

(1) Activating strains:

the human recombinant arginase I-producing strain constructed in example 1 was streaked onto LB plates containing 100. mu.g/ml ampicillin, and cultured at 33 ℃ for 24 hours.

(2) Culturing the first-class strain:

1-inoculated mycelia were streaked from the plate and inoculated into a primary seed medium (LB liquid medium supplemented with 50ppm ampicillin) and cultured at 33 ℃ and pH7.0 at 200rpm for 18 hours.

(3) And (3) secondary seed culture:

the primary seed liquid was inoculated in a secondary seed medium (LB liquid culture supplemented with 50ppm ampicillin) at an inoculum size of 1% (volume fraction)Medium), Dissolved Oxygen (DO) 20-40% at 33 deg.C, and culturing until the OD is 100 times diluted with fermentation liquid_600nmThe value was 0.5.

(4) Fermentation culture:

inoculating the secondary seed liquid of the L-ornithine production bacteria into a fermentation tank (18L) containing a fermentation culture medium for fermentation culture, wherein the inoculation amount of the secondary seed liquid is 4% of the weight of the fermentation culture medium, the temperature of the fermentation culture is 33 ℃, the pH value is 7.0, the Dissolved Oxygen (DO) is 20-40%, and the stirring speed is 200 rpm; performing fermentation culture until the OD of the fermentation liquid after being diluted by 100 times₆₀₀When the value is 0.60, cooling to 22 ℃, adding IPTG into the system to ensure that the final concentration of the IPTG in the system is 0.2mmol/L, and carrying out induced culture for 26 h;

the fermentation medium comprises the following components: peptone 12g/L, glycerin 10g/L, yeast extract 8g/L, sodium chloride 3g/L, ammonium sulfate 2.5g/L, dipotassium hydrogen phosphate trihydrate 4g/L, ferric ammonium citrate 0.3g/L, citric acid 2.1g/L, magnesium sulfate heptahydrate 0.5g/L, and ampicillin 100 ppm.

Monitoring the glycerol content of the system during the culture process, starting to add the supplementary material when the glycerol content of the system is less than or equal to 1.0g/L, and keeping the glycerol content of the system at 0.5-1g/L by feeding the supplementary material. The supplementary material contains 400g/L of glycerol, 30g/L of peptone and 100g/L of yeast extract.

In the above fermentation process, Dissolved Oxygen (DO) is measured with dissolved oxygen electrode, and the dissolved oxygen is set to 100% with the dissolved oxygen level of the dissolved oxygen electrode in air, and 0 with the dissolved oxygen in saturated sodium sulfite solution. OD₆₀₀And pH was determined using a sample.

(5) Collection of human recombinant arginase I:

adjusting the pH value of the fermentation liquor after induction culture in the step (4) to 7.1-7.3, and crushing by a homogenizer. Passing the crushed mixed homogenate of the cells through a ceramic membrane, and collecting filtrate; the aperture of the ceramic membrane is 100nm, and the pressure is 0.5 MPa.

Diluting the filtrate to arginase concentration of 10g/L, adding PBS to make the concentration of PBS 50mM, passing through nickel column at flow rate of 3m³/h。

Nickel column affinity chromatography conditions: the filtrate was hung on a column using 50mM PBS as a binding buffer.

Dissolving bovine thrombin with enzyme activity of 2000000U and specific activity of more than 2000U/mgpr in normal saline to obtain bovine thrombin solution, adding bovine thrombin solution for cutting (1mg arginase is cut by 2U thrombin), and cutting with digestion buffer solution of 150mM NaCl, pH7.0, digestion temperature of 30 deg.C and 10 hr. Eluting with normal saline, wherein the eluent is eluent 1.

Treatment of the nickel column: and (3) eluting the used nickel column by using 80mM imidazole phosphate buffer solution as an eluent, wherein the eluent is eluent 2, the using amount of the eluent is 5 times of the column volume, the flow rate is 50cm/h (from bottom to top), and the eluent 2 is collected and discharged into a sewage treatment pool.

Eluent 1 was run through benzamidine-sepharose resin to remove bovine thrombin, benzamidine-sepharose resin equilibration buffer: 50mM Tris-HCl, 0.5M NaCl, pH7.4, and bovine thrombin is absorbed by a binding buffer (50mM Tris-HCl, 0.5M NaCl, pH7.4100cm/h 0.3MPa) and then recovered, and the bovine thrombin can be reused after specific activity determination.

Treatment of benzamidine-sepharose resin: the used benzamidine-Sepharose resin eluent 10mM HCl, 0.5M N acetylcysteine, pH2.0, and the eluent here is eluent 3. The eluent was used in an amount of 5 column volumes at a flow rate of 50 cm/h.

Pumping the eluent 3 into an electrodialysis device, adjusting the pH value of the feed liquid to 5.92 by using dilute sulfuric acid or ammonia water, starting the electrodialysis, controlling the pH value to 5.92, controlling the temperature to be below 40 ℃, and closing the electrodialysis when the conductance of a fresh room is less than or equal to 1000 mus/cm, so as to discharge fresh water. And carrying out rotary evaporation on the obtained liquid at the temperature of 50 ℃, drying at the temperature of 50 ℃ after the rotary evaporation, and recovering to obtain the bovine thrombin.

And (3) after the eluent 1 passes through the benzamidine-sepharose resin, passing through Sephadex G-150 Sephadex, and collecting the effluent liquid for 3-8 h. The collected liquid was desalted by electrodialysis. Controlling the pH value of electrodialysis to be 7.25 and the temperature to be below 40 ℃; when the conductance of the dilute chamber is less than or equal to 1000 mus/cm, the electrodialysis is closed, and fresh water is discharged.

The fresh water is steamed by rotating at the temperature of 50 ℃. After crystallization, the mixture is put into an oven to be dried at the temperature of 40 ℃.

After drying, carrying out freeze drying on arginase under the conditions as follows:

pre-freezing: the temperature is reduced by 15 ℃ per minute and is reduced to-35 ℃; quick-freezing: refrigerating the plate layer at-40 ℃, putting the plate layer into a product machine for full-speed refrigeration, and starting vacuumizing after waiting for 2 hours; sublimation drying: controlling the vacuum value at 10-30 Pa; and (3) resolving and drying: slowly heating to +40 ℃, wherein the vacuum value is less than 20 Pa; and (3) closing a vacuum valve between the freeze-drying box and the condenser, observing for 60s, and finishing freeze-drying if the pressure rise is less than 0.5Pa to obtain the human recombinant arginase I freeze-dried powder.

Comparative example 1:

integrating arg1 gene shown in SEQ ID NO.4 into plasmid pHT304 by means of conventional genetic engineering to construct a recombinant expression vector; then, the constructed recombinant expression vector was introduced into BS168 Bacillus subtilis to construct a human recombinant arginase I-producing strain A, which was fermented according to the method of example 2.

Comparative example 2:

integrating arg1 gene shown in SEQ ID NO.4 into plasmid pHT304-Pg3 (constructed by the method of example 1) by means of conventional genetic engineering to construct a recombinant expression vector; then, the constructed recombinant expression vector was introduced into BS168 Bacillus subtilis to construct a human recombinant arginase I-producing strain B, which was fermented according to the method of example 2.

Comparative example 3:

integrating arg1 gene shown in SEQ ID NO.7 into plasmid pHT304 by means of conventional genetic engineering to construct a recombinant expression vector; then, the constructed recombinant expression vector was introduced into BS168 Bacillus subtilis to construct human recombinant arginase I-producing strain C, and fermentation was performed according to the method of example 2.

Comparative example 4:

the composition of the fermentation medium in example 2 was adjusted to:

peptone 12g/L, glucose 10g/L, yeast extract 8g/L, sodium chloride 3g/L, ammonium sulfate 2.5g/L, dipotassium phosphate trihydrate 4g/L, ferric ammonium citrate 0.3g/L, citric acid 2.1g/L, magnesium sulfate heptahydrate 0.5g/L, and ampicillin 100 ppm.

The composition of the supplemented materials was adjusted to glucose 70g/L, peptone 30g/L, yeast extract 100 g/L.

Monitoring the glucose content of the system in the culture process, starting to add the supplementary material when the glucose content of the system is less than or equal to 1.0g/L, and keeping the glucose content of the system at 0.5-1g/L by feeding the supplementary material.

The other conditions were the same as in example 2.

Test example:

the concentration and the enzyme activity of the human recombinant arginase I in the filtrate collected after the ceramic membrane is passed through the ceramic membranes in example 2 and comparative examples 1 to 4 are detected, and the specific detection method is as follows:

(1) the concentration of human recombinant arginase I in the filtrate was measured by a human arginase ELISA kit (

Human Arginase 1ELISA Kit, CODE: ELH-ARG1-1), and the detection method refers to the Kit instruction.

(2) The enzymatic activity of human recombinant arginase I was tested by detecting the amount of urea: urea forms a specific red complex with oPA and NED, and the shade of the color is proportional to the activity of arginase. 50 μ L of the reaction system, where 25 μ L of enzyme, 5 μ L of substrate are arginine plus Mn²⁺(arginine and Mn)²⁺Volume ratio of 1:1), reacting at 37 deg.C for 2 hr with 20 μ L of other substances affecting enzyme activity, adding 200 μ L of cold color development terminating solution (0.6mol/L sulfuric acid, 50mmol/L boric acid, 1.6mmol/L oPA, 0.8mmol/L NED), standing at room temperature for color development for 20min, and measuring absorbance at 520nm with enzyme-labeling instrument.

Definition of enzyme activity unit (U) the amount of enzyme required to produce 1. mu. mol urea per minute at 37 ℃ is defined as one activity unit.

The activity unit of the enzyme is proportional to the reaction rate, so the activity of the enzyme can be characterized by the reaction rate under a certain enzyme and substrate concentration.

The results are shown in Table 1.

Table 1:

the above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.

SEQUENCE LISTING

<110> Zea Jia He Biotech Co., Ltd, Xintai City

<120> a method for producing human recombinant arginase I by fermentation

<130> 2021

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 366

<212> DNA

<213> Pg3 promoter

<400> 1

atatgagcac tctttccact atccctacag tgttatggct tgaacaatca cgaaacaata 60

attggtacgt acgatctttc agccgactca aacatcaaat cttacaaatg tagtctttga 120

aagtattaca tatgtaagat ttaaatgcaa ccgttttttc ggaaggaaat gatgacctcg 180

tttccaccgg aattagcttg gtaccagcta ttgtaacata atcggtacgg gggtgaaaaa 240

gctaacggaa aagggagcgg aaaagaatga tgtaagcgtg aaaaattttt tatcttatca 300

cttgacattg gaagggagat tctttataat aagaatgtgg aattgtgagc ggataacaat 360

ttcaac 366

<210> 2

<211> 3461

<212> DNA

<213> plasmid pHT304-Pg3

<400> 2

ccatcctcca aagttggaga gtgagtttta tgtcgcaaat attaatgttt ctggtgaacc 60

ttatcaaatt ttcgttgatt taatagaaac atagcggtaa aattagcagt aacttaatag 120

aacggaaatg aaaaaagcca ctctcatatg agcactcttt ccactatccc tacagtgtta 180

tggcttgaac aatcacgaaa caataattgg tacgtacgat ctttcagccg actcaaacat 240

caaatcttac aaatgtagtc tttgaaagta ttacatatgt aagatttaaa tgcaaccgtt 300

ttttcggaag gaaatgatga cctcgtttcc accggaatta gcttggtacc agctattgta 360

acataatcgg tacgggggtg aaaaagctaa cggaaaaggg agcggaaaag aatgatgtaa 420

gcgtgaaaaa ttttttatct tatcacttga cattggaagg gagattcttt ataataagaa 480

tgtggaattg tgagcggata acaatttcaa ctcaactgtt tactaaaaat cagtttcatc 540

aagcaatgaa acacgccaaa gtaaacaatt taagtaccat tacttatgag caagtattgt 600

ctatttttaa tagttatcta ttatttaacg ggaggaaata attctatgag tcgctttttt 660

aaatttggaa agttacacgt tactaaaggg aatggagata aattattaga tatactactg 720

acagcttcca agaaggtaaa gaggtcccta gcgcctacgg ggaatttgta tcgggattga 780

aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgcggca 840

ttttgccttc ctgtttttgc tcacccagaa acgctggtga aagtaaaaga tgctgaagat 900

cagttgggtg cacgagtggg ttacatcgaa ctggatctca acagcggtaa gatccttgag 960

agttttcgcc ccgaagaacg ttttccaatg atgagcactt ttaaagttct gctatgtggc 1020

gcggtattat cccgtattga cgccgggcaa gagcaactcg gtcgccgcat acactattct 1080

cagaatgact tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca 1140

gtaagagaat tatgcagtgc tgccataacc atgagtgata acactgcggc caacttactt 1200

ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat 1260

gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt 1320

gacaccacga tgcctgtagc aatggcaaca acgttgcgca aactattaac tggcgaacta 1380

cttactctag cttcccggca acaattaata gactggatgg aggcggataa agttgcagga 1440

ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc tggagccggt 1500

gagcgtgggt ctcgcggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc 1560

gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct 1620

gagataggtg cctcactgat taagcattgg taactgtcag accaagttta ctcatatata 1680

ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt 1740

gataatctca tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc 1800

gtagaaaaga tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg 1860

caaacaaaaa aaccaccgct accagcggtg gtttgtttgc cggatcaaga gctaccaact 1920

ctttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagtg 1980

tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg 2040

ctaatcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac 2100

tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca 2160

cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagctatga 2220

gaaagcgcca cgcttcccga agggagaaag gcggacaggt atccggtaag cggcagggtc 2280

ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagtcct 2340

gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg 2400

agcctatgga aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct 2460

tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc 2520

tttgagtgag ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc 2580

gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat 2640

taatgcagct ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt 2700

aatgtgagtt agctcactca ttaggcaccc caggctttac actttatgct tccggctcgt 2760

atgttgtgtg gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat 2820

tacgccaagc ttgcatgcct gcaggtcgac tctagaggat ccccgggtac cgagctcgaa 2880

ttcactggcc gtcgttttac aacgtcgtga ctgggaaaac cctggcgtta cccaacttaa 2940

tcgccttgca gcacatcccc ctttcgccag ctggcgtaat agcgaagagg cccgcaccga 3000

tcgcccttcc caacagttgc gcagcctgaa tggcgaatgg cgcctgatgc ggtattttct 3060

ccttacgcat ctgtgcggta tttcacaccg catatggtgc actctcagta caatctgctc 3120

tgatgccgca tagttaagcc agccccgaca cccgccaaca cccgctgacg cgccctgacg 3180

ggcttgtctg ctcccggcat ccgcttacag acaagctgtg accgtctccg ggagctgcat 3240

gtgtcagagg ttttcaccgt catcaccgaa acgcgcgaga cgaaagggcc tcgtgatacg 3300

cctattttta taggttaatg tcatgataat aatggtttct tagacgtcag gtggcacttt 3360

tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta 3420

tccgctcatg agacaataac cctgataaat gcttcaataa t 3461

<210> 3

<211> 322

<212> PRT

<213> arginase I of human origin

<400> 3

Met Ser Ala Lys Ser Arg Thr Ile Gly Ile Ile Gly Ala Pro Phe Ser

1 5 10 15

Lys Gly Gln Pro Arg Gly Gly Val Glu Glu Gly Pro Thr Val Leu Arg

20 25 30

Lys Ala Gly Leu Leu Glu Lys Leu Lys Glu Gln Glu Cys Asp Val Lys

35 40 45

Asp Tyr Gly Asp Leu Pro Phe Ala Asp Ile Pro Asn Asp Ser Pro Phe

50 55 60

Gln Ile Val Lys Asn Pro Arg Ser Val Gly Lys Ala Ser Glu Gln Leu

65 70 75 80

Ala Gly Lys Val Ala Glu Val Lys Lys Asn Gly Arg Ile Ser Leu Val

85 90 95

Leu Gly Gly Asp His Ser Leu Ala Ile Gly Ser Ile Ser Gly His Ala

100 105 110

Arg Val His Pro Asp Leu Gly Val Ile Trp Val Asp Ala His Thr Asp

115 120 125

Ile Asn Thr Pro Leu Thr Thr Thr Ser Gly Asn Leu His Gly Gln Pro

130 135 140

Val Ser Phe Leu Leu Lys Glu Leu Lys Gly Lys Ile Pro Asp Val Pro

145 150 155 160

Gly Phe Ser Trp Val Thr Pro Cys Ile Ser Ala Lys Asp Ile Val Tyr

165 170 175

Ile Gly Leu Arg Asp Val Asp Pro Gly Glu His Tyr Ile Leu Lys Thr

180 185 190

Leu Gly Ile Lys Tyr Phe Ser Met Thr Glu Val Asp Arg Leu Gly Ile

195 200 205

Gly Lys Val Met Glu Glu Thr Leu Ser Tyr Leu Leu Gly Arg Lys Lys

210 215 220

Arg Pro Ile His Leu Ser Phe Asp Val Asp Gly Leu Asp Pro Ser Phe

225 230 235 240

Thr Pro Ala Thr Gly Thr Pro Val Val Gly Gly Leu Thr Tyr Arg Glu

245 250 255

Gly Leu Tyr Ile Thr Glu Glu Ile Tyr Lys Thr Gly Leu Leu Ser Gly

260 265 270

Leu Asp Ile Met Glu Val Asn Pro Ser Leu Gly Lys Thr Pro Glu Glu

275 280 285

Val Thr Arg Thr Val Asn Thr Ala Val Ala Ile Thr Leu Ala Cys Phe

290 295 300

Gly Leu Ala Arg Glu Gly Asn His Lys Pro Ile Asp Tyr Leu Asn Pro

305 310 315 320

Pro Lys

<210> 4

<211> 969

<212> DNA

<213> arginase I of human origin

<400> 4

atgagcgcca agtccagaac catagggatt attggagctc ctttctcaaa gggacagcca 60

cgaggagggg tggaagaagg ccctacagta ttgagaaagg ctggtctgct tgagaaactt 120

aaagaacaag agtgtgatgt gaaggattat ggggacctgc cctttgctga catccctaat 180

gacagtccct ttcaaattgt gaagaatcca aggtctgtgg gaaaagcaag cgagcagctg 240

gctggcaagg tggcagaagt caagaagaac ggaagaatca gcctggtgct gggcggagac 300

cacagtttgg caattggaag catctctggc catgccaggg tccaccctga tcttggagtc 360

atctgggtgg atgctcacac tgatatcaac actccactga caaccacaag tggaaacttg 420

catggacaac ctgtatcttt cctcctgaag gaactaaaag gaaagattcc cgatgtgcca 480

ggattctcct gggtgactcc ctgtatatct gccaaggata ttgtgtatat tggcttgaga 540

gacgtggacc ctggggaaca ctacattttg aaaactctag gcattaaata cttttcaatg 600

actgaagtgg acagactagg aattggcaag gtgatggaag aaacactcag ctatctacta 660

ggaagaaaga aaaggccaat tcatctaagt tttgatgttg acggactgga cccatctttc 720

acaccagcta ctggcacacc agtcgtggga ggtctgacat acagagaagg tctctacatc 780

acagaagaaa tctacaaaac agggctactc tcaggattag atataatgga agtgaaccca 840

tccctgggga agacaccaga agaagtaact cgaacagtga acacagcagt tgcaataacc 900

ttggcttgtt tcggacttgc tcgggagggt aatcacaagc ctattgacta ccttaaccca 960

cctaagtaa 969

<210> 5

<211> 322

<212> PRT

<213> human recombinant arginase I

<400> 5

Met Ser Ala Lys Ser Arg Thr Ile Gly Ile Ile Gly Ala Pro Phe Ser

1 5 10 15

Lys Gly Gln Pro Arg Gly Gly Val Glu Glu Gly Pro Thr Val Leu Arg

20 25 30

Lys Ala Gly Leu Leu Glu Lys Leu Lys Glu Gln Glu Cys Asp Val Lys

35 40 45

Asp Tyr Gly Asp Leu Pro Phe Ala Asp Ile Pro Asn Asp Ser Pro Phe

50 55 60

Gln Ile Val Lys Asn Pro Arg Ser Val Gly Lys Ala Ser Glu Gln Leu

65 70 75 80

Ala Gly Lys Val Ala Glu Val Lys Lys Asn Gly Arg Ile Ser Leu Val

85 90 95

Leu Gly Gly Asp His Ser Leu Ala Ile Gly Ser Ile Ser Gly His Ala

100 105 110

Arg Val His Pro Asp Leu Gly Val Ile Trp Val Asp Ala His Thr Asp

115 120 125

Ile Asn Thr Pro Leu Thr Thr Thr Ser Gly Asn Leu His Gly Gln Pro

130 135 140

Val Ser Phe Leu Leu Lys Glu Leu Lys Gly Lys Ile Pro Glu Val Pro

145 150 155 160

Gly Phe Ser Trp Val Thr Pro Cys Ile Ser Ala Lys Asp Ile Val Tyr

165 170 175

Ile Gly Leu Arg Asp Val Asp Pro Gly Glu His Tyr Ile Leu Lys Thr

180 185 190

Leu Gly Ile Lys Tyr Phe Ser Met Thr Glu Val Asp Arg Leu Gly Ile

195 200 205

Gly Lys Val Met Glu Glu Thr Leu Ser Tyr Leu Leu Gly Arg Lys Lys

210 215 220

Arg Pro Ile His Leu Ser Phe Asp Val Asp Gly Leu Asp Pro Ser Phe

225 230 235 240

Thr Pro Ala Thr Gly Thr Pro Val Val Gly Gly Leu Thr Tyr Arg Glu

245 250 255

Gly Leu Tyr Ile Thr Glu Glu Ile Tyr Lys Thr Gly Leu Leu Ser Gly

260 265 270

Leu Asp Ile Met Glu Val Asn Pro Ser Leu Gly Lys Thr Pro Glu Glu

275 280 285

Val Thr Arg Thr Val Asn Thr Ala Val Ala Ile Thr Leu Ala Cys Phe

290 295 300

Gly Leu Ala Arg Glu Gly Asn His Lys Pro Ile Asp Tyr Leu Asn Pro

305 310 315 320

Pro Lys

<210> 6

<211> 69

<212> DNA

<213> Signal peptide

<400> 6

atgaaaagat ttttgtccac tttgttgatt ggaatgatgc tggttacatg tgcctcgccg 60

gcatttgcc 69

<210> 7

<211> 1103

<212> DNA

<213> optimized and modified arg1 Gene

<400> 7

gcatatgaaa agatttttgt ccactttgtt gattggaatg atgctggtta catgtgcctc 60

gccggcattt gccggccgcg gcgatgtctg ctaaatctcg tacaatcggc atcatcggcg 120

ctcctttctc taaaggccaa cctcgtggcg gcgttgaaga aggccctaca gttcttcgta 180

aagctggcct tcttgaaaaa cttaaagaac aagaatgcga tgttaaagat tacggcgatc 240

ttcctttcgc tgatatccct aacgattctc ctttccaaat cgttaaaaac cctcgttctg 300

ttggcaaagc ttctgaacaa cttgctggca aagttgctga agttaaaaaa aacggccgta 360

tctctcttgt tcttggcggc gatcattctc ttgctatcgg ctctatctct ggccatgctc 420

gtgttcatcc tgatcttggc gttatctggg ttgatgctca tacagatatc aacacacctc 480

ttacaacaac atctggcaac cttcatggcc aacctgtttc tttccttctt aaagaactta 540

aaggcaaagg acctgaagtt cctggcttct cttgggttac accttgcatc tctgctaaag 600

atatcgttta catcggcctt cgtgatgttg atcctggcga acattacatc cttaaaacac 660

ttggcatcaa atacttctct atgacagaag ttgatcgtct tggcatcggc aaagttatgg 720

aagaaacact ttcttacctt cttggccgta aaaaacgtcc tatccatctt tctttcgatg 780

ttgatggcct tgatccttct ttcacacctg ctacaggcac acctgttgtt ggcggcctta 840

cataccgtga aggcctttac atcacagaag aaatctacaa aacaggcctt ctttctggcc 900

ttgatatcat ggaagttaac ccttctcttg gcaaaacacc tgaagaagtt acacgtacag 960

ttaacacagc tgttgctatc acacttgctt gcttcggcct tgctcgtgaa ggcaaccata 1020

aacctatcga ttaccttaac cctcctaaag gccgcggcgc atcatcatca tcatcatcat 1080

catcatcatt aataataagt acc 1103

<210> 8

<211> 4525

<212> DNA

<213> recombinant expression vector (pHT304-Pg3-arg1)

<400> 8

ccatcctcca aagttggaga gtgagtttta tgtcgcaaat attaatgttt ctggtgaacc 60

ttatcaaatt ttcgttgatt taatagaaac atagcggtaa aattagcagt aacttaatag 120

aacggaaatg aaaaaagcca ctctcatatg agcactcttt ccactatccc tacagtgtta 180

tggcttgaac aatcacgaaa caataattgg tacgtacgat ctttcagccg actcaaacat 240

caaatcttac aaatgtagtc tttgaaagta ttacatatgt aagatttaaa tgcaaccgtt 300

ttttcggaag gaaatgatga cctcgtttcc accggaatta gcttggtacc agctattgta 360

acataatcgg tacgggggtg aaaaagctaa cggaaaaggg agcggaaaag aatgatgtaa 420

gcgtgaaaaa ttttttatct tatcacttga cattggaagg gagattcttt ataataagaa 480

tgtggaattg tgagcggata acaatttcaa ctcaactgtt tactaaaaat cagtttcatc 540

aagcaatgaa acacgccaaa gtaaacaatt taagtaccat tacttatgag caagtattgt 600

ctatttttaa tagttatcta ttatttaacg ggaggaaata attctatgag tcgctttttt 660

aaatttggaa agttacacgt tactaaaggg aatggagata aattattaga tatactactg 720

acagcttcca agaaggtaaa gaggtcccta gcgcctacgg ggaatttgta tcgggattga 780

aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgcggca 840

ttttgccttc ctgtttttgc tcacccagaa acgctggtga aagtaaaaga tgctgaagat 900

cagttgggtg cacgagtggg ttacatcgaa ctggatctca acagcggtaa gatccttgag 960

agttttcgcc ccgaagaacg ttttccaatg atgagcactt ttaaagttct gctatgtggc 1020

gcggtattat cccgtattga cgccgggcaa gagcaactcg gtcgccgcat acactattct 1080

cagaatgact tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca 1140

gtaagagaat tatgcagtgc tgccataacc atgagtgata acactgcggc caacttactt 1200

ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat 1260

gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt 1320

gacaccacga tgcctgtagc aatggcaaca acgttgcgca aactattaac tggcgaacta 1380

cttactctag cttcccggca acaattaata gactggatgg aggcggataa agttgcagga 1440

ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc tggagccggt 1500

gagcgtgggt ctcgcggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc 1560

gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct 1620

gagataggtg cctcactgat taagcattgg taactgtcag accaagttta ctcatatata 1680

ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt 1740

gataatctca tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc 1800

gtagaaaaga tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg 1860

caaacaaaaa aaccaccgct accagcggtg gtttgtttgc cggatcaaga gctaccaact 1920

ctttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagtg 1980

tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg 2040

ctaatcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac 2100

tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca 2160

cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagctatga 2220

gaaagcgcca cgcttcccga agggagaaag gcggacaggt atccggtaag cggcagggtc 2280

ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagtcct 2340

gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg 2400

agcctatgga aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct 2460

tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc 2520

tttgagtgag ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc 2580

gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat 2640

taatgcagct ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt 2700

aatgtgagtt agctcactca ttaggcaccc caggctttac actttatgct tccggctcgt 2760

atgttgtgtg gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat 2820

tacgccaagc ttgcatatga aaagattttt gtccactttg ttgattggaa tgatgctggt 2880

tacatgtgcc tcgccggcat ttgccggccg cggcgatgtc tgctaaatct cgtacaatcg 2940

gcatcatcgg cgctcctttc tctaaaggcc aacctcgtgg cggcgttgaa gaaggcccta 3000

cagttcttcg taaagctggc cttcttgaaa aacttaaaga acaagaatgc gatgttaaag 3060

attacggcga tcttcctttc gctgatatcc ctaacgattc tcctttccaa atcgttaaaa 3120

accctcgttc tgttggcaaa gcttctgaac aacttgctgg caaagttgct gaagttaaaa 3180

aaaacggccg tatctctctt gttcttggcg gcgatcattc tcttgctatc ggctctatct 3240

ctggccatgc tcgtgttcat cctgatcttg gcgttatctg ggttgatgct catacagata 3300

tcaacacacc tcttacaaca acatctggca accttcatgg ccaacctgtt tctttccttc 3360

ttaaagaact taaaggcaaa ggacctgaag ttcctggctt ctcttgggtt acaccttgca 3420

tctctgctaa agatatcgtt tacatcggcc ttcgtgatgt tgatcctggc gaacattaca 3480

tccttaaaac acttggcatc aaatacttct ctatgacaga agttgatcgt cttggcatcg 3540

gcaaagttat ggaagaaaca ctttcttacc ttcttggccg taaaaaacgt cctatccatc 3600

tttctttcga tgttgatggc cttgatcctt ctttcacacc tgctacaggc acacctgttg 3660

ttggcggcct tacataccgt gaaggccttt acatcacaga agaaatctac aaaacaggcc 3720

ttctttctgg ccttgatatc atggaagtta acccttctct tggcaaaaca cctgaagaag 3780

ttacacgtac agttaacaca gctgttgcta tcacacttgc ttgcttcggc cttgctcgtg 3840

aaggcaacca taaacctatc gattacctta accctcctaa aggccgcggc gcatcatcat 3900

catcatcatc atcatcatca ttaataataa gtaccgagct cgaattcact ggccgtcgtt 3960

ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcacat 4020

ccccctttcg ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 4080

ttgcgcagcc tgaatggcga atggcgcctg atgcggtatt ttctccttac gcatctgtgc 4140

ggtatttcac accgcatatg gtgcactctc agtacaatct gctctgatgc cgcatagtta 4200

agccagcccc gacacccgcc aacacccgct gacgcgccct gacgggcttg tctgctcccg 4260

gcatccgctt acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca 4320

ccgtcatcac cgaaacgcgc gagacgaaag ggcctcgtga tacgcctatt tttataggtt 4380

aatgtcatga taataatggt ttcttagacg tcaggtggca cttttcgggg aaatgtgcgc 4440

ggaaccccta tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa 4500

taaccctgat aaatgcttca ataat 4525

Claims (9)

1. A method for producing human recombinant arginase I by fermentation is characterized by comprising the following steps:

(1) inoculating the seed liquid of the human recombinant arginase I producing strain into a fermentation culture medium for fermentation culture, wherein the temperature of the fermentation culture is 32-34 ℃, the pH value is 6.8-7.2, the dissolved oxygen is 20-40%, and the stirring speed is 180-220 rpm; performing fermentation culture until the OD of the fermentation liquid after being diluted by 100 times₆₀₀When the value is 0.50-0.60, cooling to 22 ℃, adding IPTG into the system to ensure that the final concentration of the IPTG in the system is 0.2mmol/L, and carrying out induced culture for 20-28 h;

monitoring the glycerol content of the system in the culture process, starting to add supplementary materials when the glycerol content of the system is less than or equal to 1.0g/L, and keeping the glycerol content of the system at 0.5-1g/L by feeding supplementary materials;

(2) adjusting the pH value of the culture solution after induction culture in the step (1) to 7.1-7.3, and crushing the culture solution by a homogenizer; passing the crushed mixed homogenate of the cells through a ceramic membrane, and collecting filtrate; diluting the filtrate until the concentration of human recombinant arginase I in the filtrate is 8-12g/L, carrying out affinity chromatography by adopting a nickel column, carrying out column hanging on the diluted filtrate, then adding a bovine thrombin solution for cutting, eluting by using normal saline, and collecting eluent; passing the eluate through benzamidine-sepharose resin to remove bovine thrombin; passing the eluent which passes through the benzamidine-sepharose resin through Sephadex G-150 Sephadex, and collecting liquid flowing out for 3-8 h; desalting the collected liquid by electrodialysis, collecting fresh water, concentrating and drying to obtain the human recombinant arginase I.

2. The method according to claim 1, wherein in step (1), the human recombinant arginase I-producing strain is constructed by the following method:

carrying out double digestion treatment on the pHT304 plasmid by Nde I and HincII, and integrating a Pg3 promoter sequence shown in SEQ ID NO.1 onto the pHT304 plasmid after double digestion treatment to obtain a plasmid pHT304-Pg3, wherein the nucleotide sequence of the plasmid pHT304-Pg3 is shown in SEQ ID NO. 2; carrying out double digestion treatment on the plasmid pHT304-Pg3 by using Sph I and Sac I, and integrating arg1 gene into the plasmid pHT304-Pg3 subjected to double digestion treatment to obtain a recombinant expression vector, wherein the nucleotide sequence of the recombinant expression vector is shown as SEQ ID No. 8;

and introducing the obtained recombinant expression vector into bacillus subtilis to construct and obtain the human recombinant arginase I producing strain.

3. The method according to claim 2, wherein the nucleotide sequence of arg1 gene is shown in SEQ ID No. 7.

4. The method according to claim 1, wherein in step (1), the composition of the fermentation medium is: peptone 12g/L, glycerin 10g/L, yeast extract 8g/L, sodium chloride 3g/L, ammonium sulfate 2.5g/L, dipotassium hydrogen phosphate trihydrate 4g/L, ferric ammonium citrate 0.3g/L, citric acid 2.1g/L, magnesium sulfate heptahydrate 0.5g/L, and ampicillin 100 ppm.

5. The method according to claim 1, wherein in the step (1), the feed comprises 400g/L of glycerol, 30g/L of peptone and 100g/L of yeast extract.

6. The method of claim 1, wherein in step (2), the specific conditions for adding the bovine thrombin solution for cleavage are as follows: the digestion buffer was cut with 150mM NaCl, pH7.0, digestion temperature 30 ℃ for 10 h.

7. The method of claim 1, wherein in step (2), the electrodialysis conditions are: controlling the pH value to be 7.25 and the temperature to be below 40 ℃; when the conductance of the dilute chamber is less than or equal to 1000 mus/cm, the electrodialysis is closed, and fresh water is discharged.

8. The method according to claim 1, wherein in the step (2), the drying is freeze-drying under the following conditions:

pre-freezing: the temperature is reduced by 15 ℃ per minute and is reduced to-35 ℃; quick-freezing: refrigerating the plate layer at-40 ℃, putting the plate layer into a product machine for full-speed refrigeration, and starting vacuumizing after waiting for 2 hours; sublimation drying: controlling the vacuum value at 10-30 Pa; and (3) resolving and drying: slowly heating to +40 ℃, wherein the vacuum value is less than 20 Pa; and (5) closing a vacuum valve between the freeze-drying box and the condenser, observing for 60s, and finishing freeze-drying if the pressure rise is less than 0.5 Pa.

9. Human recombinant arginase I produced by the method according to any one of claims 1 to 8, having the amino acid sequence shown in SEQ ID No. 5.

Images